Want to see NTHI full AI Analyst Report?
NTHI Stock Chart & Stats
$3.43
-$0.04(-1.02%)
At close: 4:00 PM EDT
$3.43
-$0.04(-1.02%)
Day’s Range― - ―
52-Week Range$3.01 - $12.99
Previous CloseN/A
Volume13.97K
Average Volume (3M)103.40K
Market Cap
$118.27M
Enterprise Value$110.08
Total Cash (Recent Filing)$1.97M
Total Debt (Recent Filing)$328.22K
Price to Earnings (P/E)―
Beta1.55
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding25,936,365
10 Day Avg. Volume39,098
30 Day Avg. Volume103,402
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-9.07
Price to Sales (P/S)3973.02
P/FCF Ratio-7.62
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.50Price Target Upside410.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Phase 2a Clinical EfficacyThe Phase 2a efficacy signal provides a meaningful foundation for FDA discussions and further trials. If validated, the durability of disease control could improve NEO100’s probability of advancing toward registration in a high-need cancer setting.
Differentiated CNS Drug-delivery PlatformA long-dated patent estate and differentiated nose-to-brain delivery approach may protect the platform from direct competition. This could support product exclusivity and multiple development opportunities across difficult-to-treat CNS cancers.
Expanding Clinical And Regulatory FootprintInternational clearances and a broader trial portfolio expand the company’s development infrastructure beyond the United States. Parallel studies can generate more clinical evidence and create multiple potential paths for platform validation.
Bears Say
Pre-revenue Operating ModelThe company lacks meaningful commercial revenue while its expense base remains substantial, leaving no operating scale to absorb costs. Sustainable value creation therefore depends on successful clinical development and eventual commercialization.
Severe And Worsening Cash BurnPersistent negative cash flow indicates that operations require substantial external funding. The deterioration from 2024 increases execution risk because additional capital will be needed to sustain trials and advance the pipeline.
Negative Equity And Dilution RiskDeeply negative equity weakens financial flexibility and raises credit concerns despite modest current debt. Convertible preferred financing can extend the runway, but future conversion may dilute existing shareholders and reflects capital-market dependence.
NeOnc Technologies Holdings, Inc. News
NTHI FAQ
What was NeOnc Technologies Holdings, Inc.’s price range in the past 12 months?
NeOnc Technologies Holdings, Inc. lowest stock price was $3.00 and its highest was $12.99 in the past 12 months.
What is NeOnc Technologies Holdings, Inc.’s market cap?
NeOnc Technologies Holdings, Inc.’s market cap is $118.27M.
When is NeOnc Technologies Holdings, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were NeOnc Technologies Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is NeOnc Technologies Holdings, Inc. overvalued?
According to Wall Street analysts NeOnc Technologies Holdings, Inc.’s price is currently Undervalued.
Does NeOnc Technologies Holdings, Inc. pay dividends?
NeOnc Technologies Holdings, Inc. does not currently pay dividends.
What is NeOnc Technologies Holdings, Inc.’s EPS estimate?
NeOnc Technologies Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NeOnc Technologies Holdings, Inc. have?
NeOnc Technologies Holdings, Inc. has 25,936,365 shares outstanding.
What happened to NeOnc Technologies Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NeOnc Technologies Holdings, Inc.?
Currently, no hedge funds are holding shares in NTHI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeOnc Technologies Holdings, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (410.20% Upside)
$17.50 (410.20% Upside)
Blogger Sentiment
Bullish
NTHI Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $318.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
75.08%
Trailing 12-Months
Company Description
NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
NTHI Stock 12 Month Forecast
Average Price Target
$17.50
▲(410.20% Upside)
Technical Analysis
Ownership Overview
49.44% Insiders
1.25% Mutual Funds
6.96% Other Institutional Investors
40.26% Public Companies and
Individual Investors